Page 110 - Human Use News Today

EbvalloTM on Track to be the First Ever Allogeneic T-Cell Therapy Approved Positive Opinion Based on Pivotal Phase 3 ALLELE Study Demonstrating a Favorable Risk-Benefit Profile European

/PRNewswire/ -- Atara Biotherapeutics, Inc. (Nasdaq: ATRA) and Pierre Fabre today announced the Committee for Medicinal Products for Human Use (CHMP) of the...

(RTTNews) - BeiGene (BGNE) announced the Committee for Medicinal Products for Human Use of the European Medicines Agency has issued a positive opi...

BeiGene Receives Positive CHMP Opinion for BRUKINSA® (zanubrutinib) for the Treatment of Adults With CLLIf approved, BRUKINSA would be the only BTK inhibitor for CLL in the European Union to achieve superior efficacy versus standard of care in head-to-head trialsWith significantly lower rates of atrial fibrillat...

/PRNewswire/ -- Pharming Group N.V. ("Pharming" or "the Company") (EURONEXT Amsterdam: PHARM/Nasdaq: PHAR) announces that it has submitted a Marketing...

Application is based on randomized, controlled and long-term extension data for leniolisib as a treatment for APDS, a rare primary immunodeficiency This submission follows the grant of

- OXLUMO Now Indicated for the Treatment of Primary Hyperoxaluria Type 1 (PH1) to Lower Urinary and Plasma Oxalate Levels in Pediatric and Adult Patie

The EMA has issued a positive opinion of the type II variation application of the JAK1 inhibitor filgotinib, based on testicular function safety data from two phase 2 clinical trials.

FN Media Group Presents Microsmallcap.com Market Commentary NEW YORK, Oct. 5, 2022 /PRNewswire/ -- A Toronto-based biotech firm is developing a new psychedelic medicine to cure Alzheimer's

/PRNewswire/ -- A Toronto-based biotech firm is developing a new psychedelic medicine to cure Alzheimers disease, announcing recently that it has gotten...